Difference between revisions of "Fruquintinib (Elunate)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== VEGFR inhibitor ==Preliminary data== ===Colon cancer=== *'''FRESCO:''' Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H,...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
||
| Line 15: | Line 15: | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 17:45, 3 February 2019
Mechanism of action
VEGFR inhibitor
Preliminary data
Colon cancer
- FRESCO: Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018 Jun 26;319(24):2486-2496. link to original article PubMed
Also known as
- Code name: HMPL-013